Anlon Healthcare Stock Price Today (NSE: AHCL)
Fundamental Score
Anlon Healthcare Share Price Live NSE/BSE & Institutional Fundamental Analysis
Anlon Healthcare share price today is ₹114.11, up +0.00% on NSE/BSE as of 18 March 2026. Anlon Healthcare (AHCL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹879.52 (Cr). The 52-week high for AHCL share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 32.28x, AHCL is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 40.45% and a debt-to-equity ratio of 0.27.
Anlon Healthcare Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Anlon Healthcare Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Anlon Healthcare Share Price: A Financial Stability Analysis
The pharmaceutical sector, often considered defensive due to consistent demand for healthcare products, faces increasing pressure from regulatory changes and the rising costs of research and development. This analysis examines the financial stability of Anlon Healthcare, focusing on its current metrics. At a trading price of ₹127.69999694824219, the Anlon Healthcare share price presents a specific valuation that warrants deeper investigation. This analysis is part of an 80-parameter fundamental audit, verified by Sweta Mishra, and aims to provide an objective assessment based on publicly available data.
Anlon Healthcare’s Price-to-Earnings (PE) ratio of 32.28 indicates how much investors are willing to pay for each rupee of earnings. When benchmarking against sector peers, it is important to assess whether this premium is justified by growth prospects and relative performance. Consider
Mankind Pharma Ltd. While a comprehensive comparison of management quality is beyond the scope of this analysis, it is an area that investors often scrutinize. For example, examining the strategic decisions and capital allocation efficiency of both companies' management teams offers insights into their long-term potential.A critical metric is Anlon Healthcare's Return on Capital Employed (ROCE) of 24.83%. ROCE measures how efficiently a company is using its capital to generate profits. A consistently high ROCE, like the one observed, can contribute to a wider economic moat, enabling the company to reinvest earnings, innovate, and potentially command pricing power. However, sustainability of this high ROCE should be examined, factoring in competitive pressures and market dynamics. Maintaining such performance over the long term would strengthen Anlon Healthcare's competitive position. The analysis observes the data points presented, and no investment recommendation is made.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Anlon Healthcare Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AHCL across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (40.45%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.83%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (16.42%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (259.85%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (115.97%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.27)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.64x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (52.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-47.27 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.83%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Anlon Healthcare Financial Statements
Comprehensive financial data for Anlon Healthcare including income statement, balance sheet and cash flow
About AHCL (Anlon Healthcare)
Anlon Healthcare (AHCL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹879.52 (Cr). Anlon Healthcare has delivered a Return on Equity (ROE) of 40.45% and a ROCE of 24.83%. The debt-to-equity ratio stands at 0.27, reflecting the company's capital structure. Investors tracking AHCL share price can monitor key metrics including P/E ratio, promoter holding of 52.68%, and quarterly earnings growth.
Company Details
Key Leadership
Latest News
AHCL Share Price: Frequently Asked Questions
What is the current share price of Anlon Healthcare (AHCL)?
As of 18 Mar 2026, 10:12 am IST, Anlon Healthcare share price is ₹114.11. The AHCL stock has a market capitalisation of ₹879.52 (Cr) on NSE/BSE.
Is AHCL share price Overvalued or Undervalued?
AHCL share price is currently trading at a P/E ratio of 32.28x, compared to the industry average of 31.77x. Based on this relative valuation, the Anlon Healthcare stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of AHCL share price?
The 52-week high of AHCL share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Anlon Healthcare share price?
Key factors influencing AHCL share price include quarterly earnings growth (Sales Growth: 115.97%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Anlon Healthcare a good stock for long-term investment?
Anlon Healthcare shows a 5-year Profit Growth of N/A% and an ROE of 40.45%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.27 before investing in AHCL shares.
How does Anlon Healthcare compare with its industry peers?
Anlon Healthcare competes with major peers in the Pharmaceuticals. Investors should compare AHCL share price P/E of 32.28x and ROE of 40.45% against the industry averages to determine competitive standing.
What is the P/E ratio of AHCL and what does it mean?
AHCL share price has a P/E ratio of 32.28x compared to the industry average of 31.77x. Investors pay ₹32 for every ₹1 of annual earnings.
How is AHCL performing according to Bull Run's analysis?
AHCL has a Bull Run fundamental score of 49/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does AHCL belong to?
AHCL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Anlon Healthcare share price.
What is Return on Equity (ROE) and why is it important for AHCL?
AHCL has an ROE of 40.45%, which indicates excellent management efficiency. ROE measures how efficiently Anlon Healthcare generates profits from shareholders capital.
How is AHCL debt-to-equity ratio and what does it indicate?
AHCL has a debt-to-equity ratio of 0.27, which indicates conservative financing with low financial risk.
What is AHCL dividend yield and is it a good dividend stock?
AHCL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Anlon Healthcare shares.
How has AHCL share price grown over the past 5 years?
AHCL has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in AHCL and why does it matter?
Promoters hold 52.68% of AHCL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Anlon Healthcare.
What is AHCL market capitalisation category?
AHCL has a market capitalisation of ₹880 crores, placing it in the Small-cap category.
How volatile is AHCL stock?
AHCL has a beta of N/A. A beta > 1 suggests the Anlon Healthcare stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is AHCL operating profit margin trend?
AHCL has a 5-year average Operating Profit Margin (OPM) of 16.42%, indicating the company's operational efficiency.
How is AHCL quarterly performance?
Recent quarterly performance shows Anlon Healthcare YoY Sales Growth of 115.97% and YoY Profit Growth of 259.85%.
What is the institutional holding pattern in AHCL?
AHCL has FII holding of 0.00% and DII holding of 2.83%. Significant institutional holding often suggests professional confidence in the Anlon Healthcare stock.